Drupal.behaviors.print = function(context) {window.print();window.close();}>
Myriad Highlights RBM Pharma Work, Reports $2M in Q4 Revenues from Companion Diagnostics
August 12, 2011
Myriad Highlights RBM Pharma Work, Reports $2M in Q4 Revenues from Companion Diagnostics
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Myriad to Enter Proteomics Market with $80M Purchase of Rules-Based Medicine
April 29, 2011 / ProteoMonitor
Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 3, 2011 / ProteoMonitor
RBM Achieves Milestone in Companion Diagnostic Project with Roche
May 27, 2011 / ProteoMonitor
Myriad Moving Eight Protein-Based Tests to Market; Priorities Include AD, Kidney Damage, Colon Cancer
November 4, 2011 / ProteoMonitor
New Alzheimer's Guidelines Call for Use of Protein Biomarkers in Clinical Research
April 22, 2011 / ProteoMonitor